Cubist Systematic Strategies LLC purchased a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 83,919 shares of the company's stock, valued at approximately $232,000. Cubist Systematic Strategies LLC owned approximately 0.13% of Inozyme Pharma as of its most recent filing with the SEC.
A number of other large investors have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in shares of Inozyme Pharma by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company's stock valued at $151,000 after acquiring an additional 6,851 shares during the period. Palumbo Wealth Management LLC raised its stake in Inozyme Pharma by 52.3% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company's stock worth $64,000 after acquiring an additional 7,995 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Inozyme Pharma by 11.6% in the fourth quarter. American Century Companies Inc. now owns 79,349 shares of the company's stock valued at $220,000 after buying an additional 8,263 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Inozyme Pharma by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company's stock valued at $3,268,000 after buying an additional 8,450 shares in the last quarter. Finally, Harvest Investment Services LLC acquired a new stake in shares of Inozyme Pharma in the fourth quarter valued at $31,000. Institutional investors own 88.30% of the company's stock.
Inozyme Pharma Price Performance
INZY remained flat at $3.96 during trading on Friday. The company had a trading volume of 1,141,608 shares, compared to its average volume of 816,327. The company has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $1.88. The stock has a market cap of $255.67 million, a P/E ratio of -2.54 and a beta of 1.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. Inozyme Pharma, Inc. has a twelve month low of $0.72 and a twelve month high of $6.24.
Inozyme Pharma (NASDAQ:INZY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). Equities analysts forecast that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current year.
Analyst Upgrades and Downgrades
INZY has been the subject of a number of research reports. Needham & Company LLC lowered Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday, May 16th. TD Cowen lowered Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Jefferies Financial Group restated a "hold" rating and issued a $4.00 target price (down previously from $15.00) on shares of Inozyme Pharma in a research note on Friday, May 16th. Wedbush cut Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of Inozyme Pharma in a research note on Thursday, April 10th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $11.75.
Read Our Latest Stock Report on Inozyme Pharma
About Inozyme Pharma
(
Free Report)
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
See Also
Before you consider Inozyme Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inozyme Pharma wasn't on the list.
While Inozyme Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
